Microbot Medical Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $71.9M
- Price
- $1.07
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 2.0M
About
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
Quick stats
Shares outstanding67.2M
Computed float67.0M
Float / shares99.8%
Cash runway (months)37
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000883975
AI Summary
AI-generated1/28
minorbullishpartnership
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Microbot Medical signed a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System throughout Israel.
The agreement follows Israeli Ministry of Health AMAR regulatory approval and registry listing in May 2026, with initial orders anticipated in Q4 2026.
The deal advances Microbot's international strategy of engaging distributors in developed markets ahead of potential entry outside the U.S., though no financial terms were disclosed.